Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Zhangzhou Pientzehuang Pharmaceutical., Ltd (600436.SS)
CNY128.32
+1.70 (+1.34%)
CN SHH Healthcare Drug Manufacturers - General
Address
Pien Tze Huang Building 363000
Zhangzhou, CN
Zhangzhou, CN
CEO
Jin Ming Huang
Website
zzpzh.com.cn
IPO
2003-06-16
ISIN CNE000001F21
Description
Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. is a Chinese company, headquartered in Zhangzhou, that specializes in the production and distribution of traditional Chinese medicines. Its offerings, predominantly sold under the renowned Pien Tze Huang brand, reach consumers both domestically within China and across international markets. Beyond its core pharmaceutical products, the company's expansive portfolio encompasses health and wellness items, beauty care products, household chemical goods, a variety of medical devices, and nutritional supplements. The firm operates as a subsidiary of Zhangzhou Jiulongjiang Group Co., Ltd.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY128.32
+1.70 (+1.34%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
3M
Beta
0.35
Float Shares
218.61M
Free Float %
36.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.04% | +1.19% | -4.95% | -10.67% | -19.67% | -14.95% | -30.09% | -47.54% | -56.63% | +291.46% | +4,637.62% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
128.32
DCF (Unlevered)
131.06
+2.1%
DCF (Levered)
119.03
-7.2%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
83% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 4 | 0 |
| Buy | 6 | 0 |
| Hold | 2 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
22.07
Safe zone
Piotroski F-Score
4 / 9
Average
MOAT Score
5 / 10
Developing
Composite Rating
B
Overall Score
3 / 5
Medium
DCF Score
4 / 5
High
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - General: +6.6%-16.6% Q1'26: -12.7% (vs Q1'25)
-
EPS growth Drug Manufacturers - General: +18.2%-27.4% Q1'26: -25.9% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - General: +36.0%-1.0% Q1'26: +41.7% (vs Q1'25)
-
EBIT margin Drug Manufacturers - General: +19.4%+25.0% ★ Q1'26: +32.2% (vs Q1'25)
-
ROIC Drug Manufacturers - General: +10.2%+12.8% ★ Q1'26: +20.1% (vs Q1'25)
-
Share dilution Drug Manufacturers - General: +0.0%-0.2% ★ Q1'26: +0.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - General: -0.29×0.44× Q1'26: 0.29× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 2 EPS Ana. |
Dec 2027 6 Rev. Ana. 7 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.89B
est: 1.79B (+5.6%)
|
2.31B
est: 2.29B (+0.7%)
|
3.71B
est: 3.50B (+6.0%)
|
4.77B
est: 4.78B (-0.4%)
|
5.72B
est: 5.77B (-0.8%)
|
6.51B
est: 6.51B (+0.0%)
|
8.02B
est: 8.01B (+0.2%)
|
8.69B
est: 8.79B (-1.1%)
|
10.06B
est: 10.66B (-5.7%)
|
10.79B
est: 10.85B (-0.5%)
|
9.00B
est: 9.78B (-7.9%)
|
9.55B
8.99B – 10.76B
-2.3% YoY
|
10.40B
9.54B – 11.67B
+8.9% YoY
|
11.47B
10.65B – 12.89B
+10.2% YoY
|
| EBITDA |
543.28M
est: 581.19M (-6.5%)
|
639.55M
est: 746.60M (-14.3%)
|
944.36M
est: 1.14B (-17.2%)
|
1.30B
est: 1.56B (-16.6%)
|
1.62B
est: 1.88B (-14.0%)
|
1.88B
est: 2.12B (-11.2%)
|
2.85B
est: 2.61B (+9.5%)
|
2.90B
est: 2.86B (+1.2%)
|
3.30B
est: 3.41B (-3.2%)
|
3.47B
est: 3.47B (+0.2%)
|
2.33B
est: 3.12B (-25.4%)
|
3.05B
2.87B – 3.44B
-2.3% YoY
|
3.32B
3.05B – 3.73B
+8.9% YoY
|
3.67B
3.40B – 4.12B
+10.2% YoY
|
| EBIT |
510.52M
est: 565.34M (-9.7%)
|
593.16M
est: 726.24M (-18.3%)
|
879.18M
est: 1.11B (-20.8%)
|
1.24B
est: 1.51B (-18.3%)
|
1.56B
est: 1.83B (-14.6%)
|
1.79B
est: 2.06B (-13.1%)
|
2.75B
est: 2.54B (+8.4%)
|
2.85B
est: 2.79B (+2.3%)
|
3.23B
est: 3.32B (-2.8%)
|
3.42B
est: 3.38B (+1.2%)
|
2.25B
est: 3.05B (-26.2%)
|
2.98B
2.80B – 3.35B
-2.3% YoY
|
3.24B
2.97B – 3.64B
+8.9% YoY
|
3.57B
3.32B – 4.02B
+10.2% YoY
|
| Net Income |
466.68M
est: 547.50M (-14.8%)
|
536.13M
est: 543.47M (-1.4%)
|
807.02M
est: 714.06M (+13.0%)
|
1.14B
est: 1.12B (+1.9%)
|
1.37B
est: 1.39B (-1.1%)
|
1.67B
est: 1.66B (+0.7%)
|
2.43B
est: 2.42B (+0.4%)
|
2.47B
est: 2.56B (-3.2%)
|
2.80B
est: 2.98B (-6.1%)
|
2.98B
est: 3.13B (-5.0%)
|
2.16B
est: 2.58B (-16.3%)
|
2.48B
2.18B – 2.79B
-3.8% YoY
|
3.06B
1.81B – 3.38B
+23.4% YoY
|
3.14B
2.85B – 3.65B
+2.6% YoY
|
| SGA |
139.12M
est: 116.60M (+19.3%)
|
488.70M
est: 149.78M (+226.3%)
|
349.71M
est: 228.93M (+52.8%)
|
337.16M
est: 312.45M (+7.9%)
|
446.57M
est: 376.84M (+18.5%)
|
584.49M
est: 425.10M (+37.5%)
|
658.52M
est: 522.96M (+25.9%)
|
396.55M
est: 574.43M (-31.0%)
|
700.77M
est: 685.24M (+2.3%)
|
425.72M
est: 697.03M (-38.9%)
|
760.19M
est: 628.29M (+21.0%)
|
613.94M
577.93M – 691.53M
-2.3% YoY
|
668.53M
612.99M – 750.11M
+8.9% YoY
|
737.04M
684.38M – 828.51M
+10.2% YoY
|
| EPS |
0.77
est: 0.91 (-15.1%)
|
0.89
est: 0.90 (-1.1%)
|
1.34
est: 1.18 (+13.3%)
|
1.89
est: 1.86 (+1.8%)
|
2.28
est: 2.30 (-0.9%)
|
2.77
est: 2.75 (+0.8%)
|
4.03
est: 4.01 (+0.5%)
|
4.10
est: 4.23 (-3.1%)
|
4.64
est: 4.94 (-6.1%)
|
4.93
est: 5.03 (-1.9%)
|
3.58
est: 4.29 (-16.6%)
|
4.12
3.61 – 4.62
-4.1% YoY
|
4.71
3.01 – 5.61
+14.5% YoY
|
5.21
4.73 – 6.05
+10.6% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-04-30 | B | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-29 | B | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | B | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | B | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | B | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | B | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | B | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | B | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | B | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | B | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | B | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-138.92M
OE per share TTM
-0.24
Owner's Yield
-0.16%
Maintenance CapEx ratio
24.95%
Maint CapEx / Avg PPE
9.5%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 132 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | KraneShares MSCI All China Health Care Index ETF KURE | 1.80% | 1.43M | 0.79% |
| 2 | HSBC MSCI China A UCITS ETF HMCT.L | 0.32% | 433.4K | 0.30% |
| 3 | Xtrackers Harvest CSI 300 China A-Shares ETF ASHR | 0.15% | 1.99M | 0.65% |
| 4 | Samsung KODEX China CSI300 ETF 283580.KS | 0.14% | 286.0K | 0.12% |
| 5 | Amundi MSCI China A UCITS ETF Acc CNAA.L | 0.14% | 202.1K | 0.35% |
| 6 | Xtrackers Harvest CSI300 UCITS ETF 1D ASHR.L | 0.14% | 442.3K | 0.65% |
| 7 | iShares MSCI China A ETF CNYA | 0.14% | 327.6K | 0.60% |
| 8 | iShares MSCI China A UCITS ETF CNYE.MI | 0.14% | 140.4K | 0.45% |
| 9 | iShares MSCI China A UCITS ETF CNYA.L | 0.14% | 4.26M | 0.40% |
| 10 | Xtrackers MSCI China A UCITS ETF 1C XX2D.L | 0.13% | 179.9K | 0.35% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
792.5K
Shares Outstanding
603.32M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Haipeng Yang | Chief Accountant & Director | — | male |
| Jin Ming Huang | GM & Director | — | male |
| Yi Xiong Shi | Deputy GM & Secretary of the Board | — | male |
| Ze Xiu Zhang | Deputy General Manager | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 600436.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
